AR080592A1 - Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso - Google Patents

Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso

Info

Publication number
AR080592A1
AR080592A1 ARP110100835A ARP110100835A AR080592A1 AR 080592 A1 AR080592 A1 AR 080592A1 AR P110100835 A ARP110100835 A AR P110100835A AR P110100835 A ARP110100835 A AR P110100835A AR 080592 A1 AR080592 A1 AR 080592A1
Authority
AR
Argentina
Prior art keywords
gip
peptide
gln
lys
glp
Prior art date
Application number
ARP110100835A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44041636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR080592A1 publication Critical patent/AR080592A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Un péptido que comprende la secuencia: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser- Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Arg-Ala -Xaa1-Val-Gln-Trp-Leu-Ile-Ala-Aib-Lys-Gly-Lys-Lys-Gln-Glu-Trp-Lys-His-Gln-Ile-Thr-Gln-Xaa2-Xaa (SEQ ID Ns:1) en donde Xaa1 en la posicion 22 es Nal o Phe; Xaa2 en la posicion 43 es Cys o ausente; Xaa3 en la posicion 44 es Cys o ausente; el aminoácido C-terminal está amidado opcionalmente; y siempre que cuando Xaa2 en la posicion 43 o Xaa3 en la posicion 44 sea Cys, entonces cualquiera o ambos son PEGilados opcionalmente. Este péptido exhibe actividad para el receptor de péptido insulinotropica dependiente de glucosa (GIP-R) y receptor de péptido 1 tipo glucagon (GLP-1-R) y son selectivos sobre el receptor de glucagon (Gluc-R). Específicamente se proveen análogos de GIP con sustituciones de aminoácido introducidas para modular la actividad para GIP-R y GLP-1-R y mantienen selectividad sobre Gluc-R. Formulacion farmacéutica que lo comprende. Su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la pérdida de peso.
ARP110100835A 2010-03-26 2011-03-16 Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso AR080592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31785010P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
AR080592A1 true AR080592A1 (es) 2012-04-18

Family

ID=44041636

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100835A AR080592A1 (es) 2010-03-26 2011-03-16 Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso

Country Status (25)

Country Link
US (1) US8815811B2 (es)
EP (1) EP2552471B1 (es)
JP (1) JP5887335B2 (es)
KR (1) KR101407775B1 (es)
CN (1) CN102821779B (es)
AR (1) AR080592A1 (es)
AU (1) AU2011232597B2 (es)
BR (1) BR112012024373A2 (es)
CA (1) CA2794664A1 (es)
CL (1) CL2012002635A1 (es)
CO (1) CO6630128A2 (es)
CR (1) CR20120457A (es)
DO (1) DOP2012000244A (es)
EA (1) EA022489B1 (es)
EC (1) ECSP12012181A (es)
ES (1) ES2568796T3 (es)
GT (1) GT201200263A (es)
MA (1) MA34077B1 (es)
MX (1) MX2012011127A (es)
PE (1) PE20130523A1 (es)
SG (1) SG184289A1 (es)
TN (1) TN2012000432A1 (es)
TW (1) TWI535450B (es)
WO (1) WO2011119657A1 (es)
ZA (1) ZA201206832B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
CL2009001424A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CA2747499A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
SG191194A1 (en) 2010-12-22 2013-07-31 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
CA2875743A1 (en) 2012-06-14 2013-12-19 Sanofi Exendin-4 peptide analogues
MX2014015558A (es) 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
AR091866A1 (es) 2012-07-23 2015-03-04 Zealand Pharma As Analogos del glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt) * 2012-12-21 2018-02-12 Sanofi Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
MY174727A (en) * 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10087229B2 (en) 2013-05-28 2018-10-02 Takeda Pharmaceutical Company Limited Peptide compound
TWI666220B (zh) 2013-10-17 2019-07-21 丹麥商西蘭製藥公司 醯化升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
CN105849122B (zh) * 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DK3212218T3 (da) 2014-10-29 2021-08-30 Zealand Pharma As GIP-agonistforbindelser og fremgangsmåder
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3699187A1 (en) * 2019-02-21 2020-08-26 Universite D'angers Peptide targeting gip and glp-2 receptors for treating bone disorders
CN110684082B (zh) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
WO2021150673A1 (en) * 2020-01-23 2021-07-29 Eli Lilly And Company Gip/glp1 co-agonist compounds
US20230103631A1 (en) 2020-03-06 2023-04-06 Sanofi Peptides as selective gip receptor agonists
EP4119570A4 (en) * 2020-03-11 2023-10-11 Anygen Co., Ltd. ANTI-DIABETES AND ANTI-OBESITY COMPOSITION COMPRISING A NEW COMPOUND
EP4317178A1 (en) * 2021-05-28 2024-02-07 Guangdong Raynovent Biotech Co., Ltd. Preparation and application of polypeptide
WO2022253202A1 (zh) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途
CA3230915A1 (en) 2021-09-06 2023-03-09 Thomas Boehme New peptides as potent and selective gip receptor agonists
KR20230037391A (ko) * 2021-09-09 2023-03-16 애니젠 주식회사 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2006121904A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
JP2008539735A (ja) * 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
EA020326B9 (ru) * 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CA2733006A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
WO2010016940A2 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения

Also Published As

Publication number Publication date
MX2012011127A (es) 2012-10-15
CL2012002635A1 (es) 2012-12-21
CO6630128A2 (es) 2013-03-01
JP5887335B2 (ja) 2016-03-16
DOP2012000244A (es) 2013-02-15
CN102821779A (zh) 2012-12-12
ES2568796T3 (es) 2016-05-04
EA022489B1 (ru) 2016-01-29
WO2011119657A1 (en) 2011-09-29
TN2012000432A1 (en) 2014-01-30
EP2552471B1 (en) 2016-03-16
CA2794664A1 (en) 2011-09-29
BR112012024373A2 (pt) 2017-01-10
CN102821779B (zh) 2015-03-11
ZA201206832B (en) 2014-03-26
KR20120133402A (ko) 2012-12-10
JP2013523647A (ja) 2013-06-17
US8815811B2 (en) 2014-08-26
AU2011232597A1 (en) 2012-08-30
EP2552471A1 (en) 2013-02-06
GT201200263A (es) 2013-12-05
MA34077B1 (fr) 2013-03-05
EA201270723A1 (ru) 2013-01-30
SG184289A1 (en) 2012-11-29
AU2011232597B2 (en) 2015-01-29
CR20120457A (es) 2012-10-16
KR101407775B1 (ko) 2014-06-17
ECSP12012181A (es) 2012-11-30
PE20130523A1 (es) 2013-04-25
TW201201829A (en) 2012-01-16
US20110237503A1 (en) 2011-09-29
TWI535450B (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
AR080592A1 (es) Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
AR079344A1 (es) Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
CL2012003641A1 (es) Compuesto analogo de glucagon que comprende sustituciones de los residuos aminoacidos en las posiciones 3 y/o 4 del glucagón nativo y que tiene actividad en el receptor de glucagon y/o el receptor de glp-1; composicion farmaceutica que comprende el compuesto; uso del compuesto para prevenir aumento de peso o promover perdida de peso en un sujeto que lo necesita.
AR079345A1 (es) Analogo peptidico de oxintomodulina
CL2011003173A1 (es) Análogo del glucagón, agonista gip y glp-1; dímero que comprende el análogo de glucagón; conjugado con el análogo; composición que comprende dicho análogo; uso para preparar un medicamento para tratar diabetes, reducir el aumento de peso o inducir la pérdida de peso.
CO6660484A2 (es) Análogos de glucagón
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20140186A1 (es) Analogos de glucagon que presentan actividad de receptor de gip
PE20100056A1 (es) Analogos de glucagon como agonistas gip
PE20160683A1 (es) Analogos de glucagon acilados
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
ZA201003019B (en) Pharmaceutical compositions comprising glp-1 peptides or exendin-4 and a basal insulin peptide
PE20090108A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20142113A1 (es) Analogos de glucagon
CL2009001424A1 (es) Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
RS53559B1 (en) INSULIN FORMULATIONS WITH LONG TERM ACTION
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
AR088161A1 (es) Analogos de glucagon
BR112012028707A2 (pt) composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
RU2015144632A (ru) Терапевтические пептиды
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
AR077455A1 (es) Preparaciones insulinicas de accion lenta
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
AR087727A1 (es) Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure